The DUS1L Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population generated from the A-549 human lung adenocarcinoma epithelial cell line, designed for loss-of-function analysis of the DUS1L gene. This polyclonal format provides a heterogeneous disruption pool, avoiding clonal selection while maintaining a representative knockout background.
The parental A-549 cell line, originally derived from a 58-year-old Caucasian male with lung adenocarcinoma, is a well-established non-small cell lung cancer (NSCLC) model. These adherent epithelial cells retain hallmark features of NSCLC and are extensively used in oncology research for studying proliferation, drug sensitivity, and signaling pathways.
DUS1L encodes a tRNA dihydrouridine synthase responsible for catalyzing the conversion of uridine to dihydrouridine in the D-loop of tRNAs. This post-transcriptional modification is essential for tRNA structural integrity and translational fidelity. DUS1L operates downstream of mTOR signaling and is transcriptionally activated by MYC, thereby integrating growth and nutrient cues with protein synthesis. The enzyme interacts with tRNA substrates and is likely a component of the dihydrouridine synthase complex. Disruption of DUS1L can dysregulate the translation of codon-biased mRNAs and perturb the phosphorylation of key translation regulators, including S6K and eIF4E, ultimately affecting cellular stress responses and proliferation.
In the context of A-549 NSCLC cells, knockout of DUS1L offers a powerful tool to examine the contribution of tRNA modifications to oncogenic phenotypes. Loss of DUS1L may impair proliferation, heighten sensitivity to oxidative stress, and diminish tumorigenic capacity by altering translational landscapes. This model facilitates dissection of the MYC-mTOR-DUS1L axis and its role in driving malignant features of lung adenocarcinoma.
These DUS1L knockout polyclonal cells are suitable for a range of applications, including investigation of tRNA modification in cancer, translational control studies, functional genomics of lung adenocarcinoma, and drug target screening. Representative assays include western blotting for translation regulators (e.g., phospho-S6K, eIF4E), tRNA modification profiling by LC-MS, proliferation and colony formation, apoptosis, migration/invasion, and drug sensitivity testing. The polyclonal nature makes them ideal for experiments requiring a genetically diverse knockout population. For further information, please contact Ascent Research.
